Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) Other Operating Expenses (2016 - 2025)

Vanda Pharmaceuticals' Other Operating Expenses history spans 16 years, with the latest figure at $5.3 million for Q4 2025.

  • For Q4 2025, Other Operating Expenses rose 29.51% year-over-year to $5.3 million; the TTM value through Dec 2025 reached $19.0 million, up 7.15%, while the annual FY2025 figure was $19.0 million, 7.15% up from the prior year.
  • Other Operating Expenses for Q4 2025 was $5.3 million at Vanda Pharmaceuticals, up from $4.4 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $6.8 million in Q3 2021 and bottomed at $3.2 million in Q3 2023.
  • The 5-year median for Other Operating Expenses is $5.1 million (2024), against an average of $5.1 million.
  • The largest annual shift saw Other Operating Expenses crashed 70.24% in 2021 before it increased 29.51% in 2025.
  • A 5-year view of Other Operating Expenses shows it stood at $6.2 million in 2021, then grew by 1.91% to $6.4 million in 2022, then crashed by 33.73% to $4.2 million in 2023, then dropped by 3.04% to $4.1 million in 2024, then increased by 29.51% to $5.3 million in 2025.
  • Per Business Quant, the three most recent readings for VNDA's Other Operating Expenses are $5.3 million (Q4 2025), $4.4 million (Q3 2025), and $4.2 million (Q2 2025).